Suppr超能文献

脂联素受体-1的表达与上皮性卵巢癌患者的预后

Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients.

作者信息

Li Xiahui, Yu Zhe, Fang Liping, Liu Fang, Jiang Kui

机构信息

Department of Oncology, The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).

Department of Oncology , The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).

出版信息

Med Sci Monit. 2017 Mar 30;23:1514-1521. doi: 10.12659/msm.899990.

Abstract

BACKGROUND Adiponectin receptor-1 (AdipoR1) has been reported to be associated with the risk of obesity-associated malignancies, including epithelial ovarian cancer (EOC). The aim of this study was to determine if AdipoR1 could serve as a prognosis indicator for patients with EOC. MATERIAL AND METHODS In this study, expression of AdipoR1 in 73 EOC patients consecutively admitted to our hospital was detected by immunohistochemical staining. Univariate and multivariate analyses were performed to assess the relationship between AdipoR1 expression level and progression-free survival (PFS) and overall survival (OS) rates in patients. RESULTS A relatively lower expression of AdipoR1 in the cancerous tissues was detected compared to normal ovarian tissues, but the difference was not significant (p>0.05). AdipoR1 expression level in EOC patients was negatively correlated with advanced FIGO stages in patients and tumor differentiation, but had no correlation with pathological types, presenting of ascites, shorter platinum-free interval (PFI), diabetes, preoperative and postoperative body mass index (BMI), or platelet counts (p>0.05). Moreover, patients with AdipoR1 expression had a significantly longer PFS and OS compared to the negative expression group (p<0.001). CONCLUSIONS Our findings suggest that AdipoR1 expression level in cancerous tissues might serve as an independent prognostic indicator in EOC patients and is associated with longer PFS and OS.

摘要

背景

据报道,脂联素受体-1(AdipoR1)与肥胖相关恶性肿瘤的风险有关,包括上皮性卵巢癌(EOC)。本研究的目的是确定AdipoR1是否可作为EOC患者的预后指标。

材料与方法

在本研究中,通过免疫组织化学染色检测了我院连续收治的73例EOC患者中AdipoR1的表达。进行单因素和多因素分析,以评估AdipoR1表达水平与患者无进展生存期(PFS)和总生存期(OS)率之间的关系。

结果

与正常卵巢组织相比,癌组织中AdipoR1的表达相对较低,但差异不显著(p>0.05)。EOC患者的AdipoR1表达水平与患者的国际妇产科联盟(FIGO)晚期分期和肿瘤分化呈负相关,但与病理类型、腹水情况、较短的无铂间期(PFI)、糖尿病、术前和术后体重指数(BMI)或血小板计数无关(p>0.05)。此外,与阴性表达组相比,AdipoR1表达阳性的患者的PFS和OS显著更长(p<0.001)。

结论

我们的研究结果表明,癌组织中AdipoR1的表达水平可能作为EOC患者的独立预后指标,并且与更长的PFS和OS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/437a25d238b6/medscimonit-23-1514-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验